
    
      OUTLINE: This is a dose-escalation study of copanlisib.

      Patients receive copanlisib intravenously (IV) and gemcitabine IV on days 1 and 8,
      carboplatin IV and rituximab IV on day 1, and dexamethasone orally (PO) or IV 30-60 minutes
      prior to chemotherapy on day 1 or PO in the morning (AM) and 30-60 minutes prior to
      chemotherapy on days 2-4. Patients also receive pegfilgrastim subcutaneously (SC) on day 8 or
      9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression
      or unacceptable toxicity.

      After completion of study treatment, patients are followed for up to 1 year.
    
  